Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, October 1998, p. 2492-2494, Vol. 42, No. 10
DDS Research
Laboratories1 and
Pharmacology
Laboratories,2 Pharmaceutical Research
Division, Takeda Chemical Industries, Ltd., Osaka, Japan
Received 15 December 1997/Returned for modification 24 March
1998/Accepted 8 July 1998
In an effort to augment the anti-Helicobacter pylori
effect of amoxicillin, mucoadhesive microspheres, which have the
ability to reside in the gastrointestinal tract for an extended period, were prepared. The microspheres contained the antimicrobial agent and
an adhesive polymer (carboxyvinyl polymer) powder dispersed in waxy
hydrogenated castor oil. The percentage of amoxicillin remaining in the
stomach both 2 and 4 h after oral administration of the
mucoadhesive microspheres to Mongolian gerbils under fed conditions was
about three times higher than that after administration in the form of
a 0.5% methylcellulose suspension. The in vivo clearance of
H. pylori following oral administration of the
mucoadhesive microspheres and the 0.5% methylcellulose suspension to
infected Mongolian gerbils was examined under fed conditions. The
mucoadhesive microspheres and the 0.5% methylcellulose suspension both
showed anti-H. pylori effects in this experimental
model of infection, but the required dose of amoxicillin was
effectively reduced by a factor of 10 when the mucoadhesive
microspheres were used. In conclusion, the mucoadhesive microspheres
more effectively cleared H. pylori from the
gastrointestinal tract than the 0.5% methylcellulose suspension due to
the prolonged gastrointestinal residence time resulting from
mucoadhesion. A dosage form consisting of mucoadhesive microspheres
containing an appropriate antimicrobial agent should be useful for the
eradication of H. pylori.
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Mucoadhesive Microspheres Containing Amoxicillin
for Clearance of Helicobacter pylori
*
Corresponding author. Mailing address: DDS Research
Laboratories, Pharmaceutical Research Division, Takeda Chemical
Industries, LTD, 17-85 Jusohonmachi 2-chome, Yodogawa-ku, Osaka, 532, Japan. Phone: 81-6-300-6082. Fax: 81-6-300-6582. E-mail:
Nagahara_Naoki{at}Takeda.co.jp.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |